Thin Mar Win

Thin Mar Win

Auto-generated profile, based on publicly available information

Thin Mar Win

Burnet Institute Myanmar Yangon Myanmar

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2024 in BMJ Open
Verified
Journal Article
Open access
PDF file
JHJulie Hennegan
Julie Hennegan
THTanvir Hasan
Tanvir Hasan
AJAbdul Jabbar
Abdul Jabbar
TJTasfiyah Jalil
Tasfiyah Jalil
EKElissa Kennedy
Elissa Kennedy
PAPeter Azzopardi
Peter Azzopardi
Background Menstrual health is essential for gender equity and the well-being of women and girls. Qualitative research has described the burden of poor menstrual health on health and education; however, these impacts have not been quantified, curtailing investment. The Adolescent Menstrual Experiences and Health Cohort (AMEHC) Study aims to describe menstrual health and its trajectories across adolescence, and quantify the relationships between menstrual health and girls’ health and education in Khulna, Bangladesh. Methods and analysis AMEHC is a prospective longitudinal cohort of 2016 adolescent girls recruited at the commencement of class 6 (secondary school, mean age=12) across 101 schools selected through a proportional random sampling approach. Each year, the cohort will be asked to complete a survey capturing (1) girls’ menstrual health and experiences, (2) support for menstrual health, and (3) health and education outcomes. Survey questions were refined through qualitative research, cognitive interviews and pilot survey in the year preceding the cohort. Girls’ guardians will be surveyed at baseline and wave 2 to capture their perspectives and household demographics. Annual assessments will capture schools’ water, sanitation and hygiene, and support for menstruation and collect data on participants’ education, including school attendance and performance (in maths, literacy). Cohort enrolment and baseline survey commenced in February 2023. Follow-up waves are scheduled for 2024, 2025 and 2026, with plans for extension. A nested subcohort will follow 406 post-menarche girls at 2-month intervals throughout 2023 (May, August, October) to describe changes across menstrual periods. This protocol outlines a priori hypotheses regarding the impacts of menstrual health to be tested through the cohort. Ethics and dissemination AMEHC has ethical approval from the Alfred Hospital Ethics Committee (369/22) and BRAC James P Grant School of Public Health Institutional Review Board (IRB-06 July 22-024). Study materials and outputs will be available open access through peer-reviewed publication and study web pages.

20 October 2023 in JGH Open
Verified
Journal Article
Open access
TWThin Mar Win
Thin Mar Win
BDBridget Louise Draper
Bridget Louise Draper
APAnna Palmer
Anna Palmer
HHHla Htay
Hla Htay
YSYi Yi Sein
Yi Yi Sein
NSNick Scott
Nick Scott
Background and Aim: The availability of direct-acting antiviral (DAA) treatment and point-of-care diagnostic testing has made hepatitis C (HCV) elimination possible even in low- and middle-income countries (LMICs); however, testing and treatment costs remain a barrier. We estimated the cost and cost-effectiveness of a decentralized community-based HCV testing and treatment program (CT2) in Myanmar.Methods: Primary cost data included the costs of DAAs, investigations, medical supplies and other consumables, staff salaries, equipment, and overheads. A deterministic cohort-based Markov model was used to estimate the average cost of care, the overall quality-adjusted life years (QALYs) gained, and the incremental cost-effectiveness ratio (ICER) of providing testing and DAA treatment compared with a modeled counterfactual scenario of no testing and no treatment.Results: From 30 January to 30 September 2019, 633 patients were enrolled, of whom 535 were HCV RNA-positive, 489 were treatment eligible, and 488 were treated. Lifetime discounted costs and QALYs of the cohort in the counterfactual no testing and no treatment scenario were estimated to be USD61790 (57 898-66 898) and 6309 (5682-6363) respectively, compared with USD123 248 (122 432-124 101) and 6518 (5894-6671) with the CT2 model of care, giving an ICER of USD294 (192-340) per QALY gained. This "one-stop-shop" model of care has a 90% likelihood of being cost-effective if benchmarked against a willingness to pay of US$300, which is 20% of Myanmar's GDP per capita (2020).Conclusions: The CT2 model of HCV care is cost-effective in Myanmar and should be expanded to meet the National Hepatitis Control Program's 2030 target, alongside increasing the affordability and accessibility of services.

15 January 2021 in Global Health Action
Verified
Journal Article
Open access
KCKarly I. Cini
Karly I. Cini
PWPhone Myint Win
Phone Myint Win
ZSZay Yar Swe
Zay Yar Swe
KTKyu Kyu Than
Kyu Kyu Than
TWThin Mar Win
Thin Mar Win
PAPeter S. Azzopardi
Peter S. Azzopardi
Background: Myanmar is a country undergoing rapid transitions in health. Its national strategic policy for young people’s health is being revised but there is a paucity of population data to inform local priorities and needs. Objective: In this paper we describe a comprehensive profile of adolescent health in Myanmar to focus policy and health actions. Methods: We used available primary data, and modelled estimates from the GBD 2017, to describe health outcomes (mortality and morbidity), health risks and determinants for adolescents in Myanmar between 1990–2017. A governance group of key stakeholders guided the framing of the study, interpretation of findings, and recommendations. Results: Overall health has improved for adolescents in Myanmar since 1990, however adolescent mortality remains high, particularly so for older adolescent males; all-cause mortality rate for 10–24 years was 70 per 100,000 for females and 149 per 100,000 for males (16,095 adolescent deaths in 2017). Overall, the dominant health problems were injuries for males and non-communicable disease for females in a context of ongoing burden of communicable and nutritional diseases for both sexes, and reproductive health needs for females. Health risks relating to undernutrition (thinness and anaemia) remain prevalent, with other health risks (overweight, binge alcohol use, and substance use) relatively low by global and regional standards but increasing. Gains have been made in social determinants such as adolescent fertility and modern contraception use; however, advances have been more limited in secondary education completion and engagement in employment and post education training. Conclusions: These results highlight the need to focus current efforts on addressing disease and mortality experienced by adolescents in Myanmar, with a specific focus on injury, mental health and non-communicable disease.

18 August 2026 in Liver International
Verified
Journal Article
Closed access
PDF file
WYWin Lei Yee
Win Lei Yee
TWThin Mar Win
Thin Mar Win
BDBridget Draper
Bridget Draper
MPMinh Duc Pham
Minh Duc Pham
MHMargaret Hellard
Margaret Hellard
SLStanley Luchters
Stanley Luchters

14 January 2026 in Global Heart
Verified
Journal Article
Open access
PDF file
TWThin Mar Win
Thin Mar Win
ALAudry Shan Yin Lee
Audry Shan Yin Lee
SSSameera Senanayake
Sameera Senanayake
NGNicholas Graves
Nicholas Graves
SKSanjeewa Kularatna
Sanjeewa Kularatna
SYSungwon Yoon
Sungwon Yoon
Background: Heart failure with reduced ejection fraction remains a major cause of morbidity and mortality despite effective treatments. Guideline-directed medical therapy, commonly referred to as quadruple therapy, reduces mortality and hospitalisation; however, uptake and dose optimisation remain suboptimal across Asia, including Singapore. This study explores barriers and enablers influencing prescribing and titration practices in a multi-ethnic Asian setting. Methods: We conducted semi-structured interviews with 38 healthcare providers from seven public healthcare institutions in Singapore, including cardiologists, clinicians from relevant subspecialties, nurses, and pharmacists. The study was informed by the Cabana framework, and data were analysed using an inductive-deductive approach. Results: Guideline awareness was generally high, but confidence in initiating and up-titrating therapy varied. Attitudinal barriers included perceived gaps between clinical trial evidence and the realities of managing diverse patient populations, safety concerns in multi-morbid patients, clinical inertia, challenges related to professional boundaries, and limited confidence among junior staff. Nonetheless, guidelines were perceived as enablers, providing a shared framework that promotes standardised care. Prescribing behaviour was shaped by patient-related factors including financial constraints, limited health literacy, cultural preferences for traditional medicines, and treatment outcomes. Organisational barriers included limited access to specialist follow-up, rotating inpatient teams, formulary gaps in primary care, and fragmented medical records. Multidisciplinary nurse- or pharmacist-led titration clinics with specialist support were a key institutional enabler. Conclusions: To narrow the guideline-practice gap, targeted toolkits and specialist support are needed to address concerns and build staff confidence. A culture of reviewing quadruple therapy prescription at discharge and during follow-up should be supported. Prescribing patterns should be monitored and reflected in real-time, and patient adherence strengthened through dedicated heart failure nurses or case managers. Telehealth or primary care-based services, increased government support for healthcare information integration, and increased financial support for patients are necessary. Lay Summary Heart failure with reduced ejection fraction is a serious medical condition that can lead to frequent hospital admissions and premature death. Clinical guidelines strongly recommend the use of four classes of evidence-based medicines, commonly known as quadruple therapy, because they can significantly improve survival and reduce hospitalisation. Despite guideline endorsement, real-world uptake and dose optimisation of quadruple therapy remains suboptimal globally. Studies on implementation barriers in adhering to the guideline recommendations for quadruple therapy have focused mainly on physicians. This study provides one of the first multi-institutional qualitative accounts of barriers and enablers in prescribing quadruple therapy or guideline-directed medical therapy (GDMT) for heart failure patients in Singapore, exploring the views of all three frontline healthcare professional groups—doctors, nurses, and pharmacists. We found that the prescription of quadruple therapy was negatively influenced by a perceived gap between clinical trial evidence and the realities of managing diverse patient populations—particularly older and multimorbid patients—alongside interprofessional relationships and limited confidence among junior staff. Health care providers’ prescribing behaviour was shaped by patient-related factors, including financial constraints, limited health literacy, and cultural preferences for traditional medicines. Limited specialist follow-up, fragmented health records, and formulary gaps in primary care hinder implementation, while positive patient outcomes and multidisciplinary care models act as enablers in adhering to guideline recommendations. The study adds context-specific implementation insights by identifying individual, organisational, and system-level factors. Specialist-supported nurse- or pharmacist-led services, primary care-based medication titration, clearer task-sharing pathways, improved decision tools, and better health information integration may enhance guideline implementation.